carpal tunnel syndrome. Carpal tunnel syndrome
Conditions
Interventions
Intervention 1: Intervention group: Only once, under ultrasound guidance, 2 cc 5% dextrose product of Shiraz Serum Pharmaceutical Company is injected through a needle gauge 23 into the carpal tunnel a
Sponsors
Shiraz University of Medical Sciences
Eligibility
Sex/Gender
All
Age
30 Years to 65 Years
Inclusion criteria
Inclusion criteria: Completing and signing the conscious consent form Age between 30 and 65 years Mild to moderate Carpal tunnel syndrome , based on electrodiagnostic criteria Paresthesia or dysesthesia or pain in the hand and wrist (which is associated with a particular condition, excessive use of the hand or the occurrence at night or relieved by shaking the hand) Existence of one of the following in the physical examination: positive Phalen test, positive Tinel test, weakness in the thenar muscles, sensory defects in the sensory area of the Median nerve in the hand It has been at least 3 months since the onset of symptoms and has not responded to non-invasive treatments
Exclusion criteria
Exclusion criteria: Positive history of polyneuropathy Positive history of surgery on involved wrist History of previous steroid injections into the affected wrist over the past year History of rheumatological diseases such as rheumatoid arthritis Pregnancy Neoplasm in involved wrist History of allergy to steroids Infection at the injection site Coagulopathies and bleeding tendency Positive history of brachial plexopathy Positive history of thoracic outlet syndrome Positive history of active radiculopathy
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Cross sectional area of median nerve. Timepoint: At the beginning of the study (before the intervention) , 1 and 3 months after the intervention (injection). Method of measurement: manual by sonography.;Median sensory nerve action potentials amplitude. Timepoint: At the beginning of the study (before the intervention) , 1 and 3 months after the intervention (injection). Method of measurement: electromyography.;Median sensory nerve action potentials latency. Timepoint: At the beginning of the study (before the intervention) , 1 and 3 months after the intervention (injection). Method of measurement: electromyography.;Median compound motor action potentials latency. Timepoint: At the beginning of the study (before the intervention) , 1 and 3 months after the intervention (injection). Method of measurement: electromyography.;Median compound muscle action potentials amplitude. Timepoint: At the beginning of the study (before the intervention) , 1 and 3 months after the intervention (injection). Method of measurement: electromyography.;Pain score by visual analogue scale. Timepoint: At the beginning of the study (before the intervention) , 1 and 3 months after the intervention (injection). Method of measurement: visual analogue scale.;Severity score by Boston carpal tunnel syndrome questionnaire. Timepoint: At the beginning of the study (before the intervention) , 1 and 3 months after the intervention (injection). Method of measurement: Boston carpal tunnel syndrome questionnaire.;Functional score by Boston carpal tunnel syndrome questionnaire. Timepoint: At the beginning of the study (before the intervention) , 1 and 3 months. Method of measurement: Boston carpal tunnel syndrome questionnaire. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactFarzaneh Rezaei motlagh
Shiraz University of Medical Sciences
Outcome results
None listed